Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Total Liabilities

Everything the company owes to creditors and other parties.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Total Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total liabilities of $15.58M in Q2 FY2026

Q2 FY2026 total liabilities was $15.58M.

Context

  • Total liabilities amounted to 12.1% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$15.58M+16.5% QoQ
Last fiscal yearDec 2025
$15.1M+3.5% YoY
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+3.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Liabilities history

USD · from the balance sheet

Latest · FY2025
15.1M USD
Year-over-year change
+3.5%
1-year CAGR
+3.5%

Total Liabilities vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
  • Total liabilities amounts to 12.1% of total assets for ATTO, versus a peer median of 22.2%.
ATTO Competitors
Total Liabilities for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$316.94M USD-18.3%-2.1%96.1%
MLTXMoonLake ImmunotherapeuticsMar 2026$146.35M USD+48.3%+145.8%36.6%
ALMSAlumis Inc. Common StockJun 2026$108.46M USD-13.6%-28.6%19.3%
ACRSAclaris Therapeutics, Inc.Mar 2026$55.07M USD+1.9%+0.2%27.7%
ORKAOruka Therapeutics, Inc.Sep 2026$33.88M USD+50.8%+127.8%2.8%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€18.7M EUR——11.3%
EVMNEvommune, Inc.Mar 2026$17.9M USD-91.6%—5.6%
QTTBQ32 Bio Inc.Mar 2026$17.36M USD-79.1%-53.2%27.3%
ATTOAttovia Therapeutics, Inc.Jun 2026$15.58M USD——12.1%
CNTBConnect Biopharma Holdings LimitedDec 2025$14.1M USD+54.6%-5.2%25.1%
ZURAZura Bio LimitedMar 2026$11.75M USD-44.3%-23.1%5.1%
Peer median (excluding ATTO) —-13.6%-3.6%22.2%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.